An observational study in Voriconazole and Fungal Infection, sponsored by Chulalongkorn University. Status unknown at 1 site in Thailand. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-24.
Sponsored by Chulalongkorn University · Observational
Invasive fungal infections are a significant cause of morbidity and mortality in immunocompromised host such as prolong neutropenic patients , post transplantation patients, malignancies or advanced AIDS . The majority of these infections were caused by Aspergillus species, which the first line of treatment is antifungal agent, Voriconazole , a triazole antifungal drug which was approved by the Food and Drug Administration in May 2002 for the treatment of invasive aspergillosis and refractory infections of Scedosporium apiospermum and Fusarium spp. There are two forms of Voriconazole , oral and intravenous form. The recommendation dose is 6 mg/kg twice daily for two dosages, followed by 4 mg/kg twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals >40 kg), followed by 200 mg twice daily, and in individuals \<40 kg the maintenance dose is 100 mg twice daily in oral form.
Voriconazole has a narrow therapeutic window and nonlinear pharmacokinetic profile with wide inter-individual and intra-individual variability, such as age, race, genotypic variation, liver dysfunction, the presence of food and drug-drug interactions with CYP450 inhibitors. These large variations in pharmacokinetics may be associated with decreased efficacy or increased toxicity. Therefore , monitoring of serum trough concentrations is recommended in the following infections: invasive aspergillosis treatment , endophthalmitis; meningitis or osteoarticular infections due to Exserohilum rostratum.
In Thai population , there are different genetic polymorphism from Caucasian ,resulting in a different response to the initial dose and there is limited resources in Thailand , mostly patients are unaccessible for Voriconazole level. Especially,in the period of starting drug, which is the critical period for patients ,most of them are post chemotherapy which may have gastrointestinal problems, mucositis , vomiting or diarrhea ,as well as receiving multiple concurrent medications. All of these affect drug absorption,drug level and efficacy of treatment. Thus, this study was designed to evaluated Voriconazole level in Thai patients in the first two week after administration.
Primary question
Secondary question
Research Design
Research Methodology
Target Population
Study population
Sample size
n= ZZ/2P(1-P) /dd
replaced P = 0.6
n = (1.96) (1.96) (0.60)(1-0.60) / (0.10)(0.10)
n =92 , sample size = 92
Study processing and data collection
Data collection
Data Analysis and Statistics
The data was analysed by computer using SPSS17 program This study used descriptive statistics ,describing general information, age, results, laboratory results and side effects of the drug in mean ,percentage or standard deviation. And used the chi-square test for analysis of the proportion of patients with serum drug levels within the therapeutic range.
This study used a confidence level of 95%, p-value less than 0.05 was statistically significant.
260 studies on the registry are indexed under Mycoses; 37 are open to participants now.
This study's planned enrollment of 92 is below the median of 153 across 85 observational studies indexed under Mycoses.
Browse Mycoses studies →Chulalongkorn University is the lead sponsor of 322 studies on the registry; 66 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Thai patient in King Chulalongkorn Memorial Hospital ,Bangkok , Thailand, age between 18 and 80 year olds ,receiving Voriconazole for treatment or prophylaxis invasive fungal infection , between 2015-2017.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient was received voriconazole according to individual indication. The starting dose is 6 mg/kg iv twice daily for two dosages, followed by 4 mg/kg iv twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals \>40 kg), followed by 200 mg twice daily, and in individuals \<40 kg the maintenance dose is 100 mg twice daily in oral form. The dosage was adjusted by drug level and toxicity. The duration of drug used was depended on indication of treatment.
Drug: Voriconazole
Percentage of patients achieved therapeutic level of voriconazole in the first two weeks after administration
Time frame: 2015-2017
Factors have significant impact to voriconazole through level .
Factors that have significant impact to voriconazole through level will be assess in this study such as drug interaction , oral mucositis .
Time frame: 2015-2017
Plan to share: No
Started Jan 2016 (actual). Primary completion is estimated for Oct 2017, 21 months after the start.
Of 28 observational studies under Mycoses, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 17. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.